Fintel reports that on October 24, 2024, UBS initiated coverage of Cullinan Therapeutics (NasdaqGS:CGEM) with a Buy recommendation.
Analyst Price Forecast Suggests 110.41% Upside
As of October 22, 2024, the average one-year price target for Cullinan Therapeutics is $33.37/share. The forecasts range from a low of $28.28 to a high of $42.00. The average price target represents an increase of 110.41% from its latest reported closing price of $15.86 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Cullinan Therapeutics is 28MM, an increase of ∞%. The projected annual non-GAAP EPS is -3.16.
What is the Fund Sentiment?
There are 315 funds or institutions reporting positions in Cullinan Therapeutics. This is an increase of 39 owner(s) or 14.13% in the last quarter. Average portfolio weight of all funds dedicated to CGEM is 0.23%, an increase of 17.51%. Total shares owned by institutions increased in the last three months by 58.53% to 66,488K shares. 
The put/call ratio of CGEM is 2.21, indicating a bearish outlook.
What are Other Shareholders Doing?
MPM Oncology Impact Management holds 7,648K shares representing 13.19% ownership of the company. No change in the last quarter.
Bvf holds 5,751K shares representing 9.92% ownership of the company. In its prior filing, the firm reported owning 3,197K shares , representing an increase of 44.41%. The firm increased its portfolio allocation in CGEM by 87.70% over the last quarter.
Deerfield Management Company, L.p. holds 3,280K shares representing 5.66% ownership of the company. In its prior filing, the firm reported owning 1,139K shares , representing an increase of 65.29%. The firm increased its portfolio allocation in CGEM by 182.00% over the last quarter.
Franklin Resources holds 2,444K shares representing 4.22% ownership of the company. In its prior filing, the firm reported owning 2,697K shares , representing a decrease of 10.34%. The firm decreased its portfolio allocation in CGEM by 84.94% over the last quarter.
Adage Capital Partners Gp, L.l.c. holds 2,233K shares representing 3.85% ownership of the company. In its prior filing, the firm reported owning 950K shares , representing an increase of 57.45%. The firm increased its portfolio allocation in CGEM by 135.97% over the last quarter.
Cullinan Oncology Background Information
(This description is provided by the company.)
Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
